Business Context and Reporting Period
This Form 8-K, dated March 6, 2018, reports on ReWalk Robotics Ltd. (noting the input metadata referenced "Lifeward Ltd." which is incorrect based on the filing text). The filing details a strategic investment agreement and the formation of a joint venture in China. The report also references financial results for the fourth quarter and fiscal year ended December 31, 2017, which were announced via press release on March 8, 2018.
Key Financial Metrics and Transaction Details
- Investment Amount: Total aggregate gross proceeds of $20 million from Timwell Corporation Limited.
- Share Issuance: 16,000,000 ordinary shares issued at $1.25 per share.
- Tranche Structure:
- First Tranche: $5 million for 4,000,000 shares.
- Second Tranche: $10 million for 8,000,000 shares.
- Third Tranche: $5 million for 4,000,000 shares.
- Ownership Impact: Post-transaction ownership for the Investor is projected to reach 34.8% after the third tranche (based on 30,006,575 shares outstanding as of March 5, 2018).
- China JV Minimum Payments: The China Joint Venture is required to make minimum cash payments to ReWalk: $1.25 million (Year 1), $4 million (Year 2), $8 million (Year 3), with annual increases of 15% for Years 4-6, 10% for Years 7-9, and 5-8% thereafter.
- Financial Results: Specific revenue, profit, or cash flow figures for the period ended December 31, 2017, are not provided in this text; they are referenced in a separate press release (Exhibit 99.2).
Material Changes and Strategic Developments
The primary material change is the entry into a definitive investment agreement with Timwell Corporation Limited. This transaction is contingent upon shareholder approval and the successful formation of a China Joint Venture (China JV) by July 1, 2018. The China JV will be owned 80% by Timwell affiliates and 20% by ReWalk. ReWalk will grant the China JV exclusive rights to market and sell its products in China, Hong Kong, and Macau.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds will be used for sales and marketing (including China expansion), reimbursement efforts, and R&D for a lightweight "soft suit" exoskeleton.
- Going Concern: The filing explicitly notes that auditors have expressed "substantial doubt" regarding ReWalk's ability to continue as a going concern based on the fiscal year ended December 31, 2017.
- Lock-up and Control: Timwell is subject to an 18-month lock-up period. Timwell will gain board appointment rights and significant voting power, potentially reaching de facto control.
- Conditions Precedent: The Second Tranche is conditioned on forming the China JV and executing license/supply agreements by July 1, 2018. The Third Tranche is conditioned on product documentation and successful local manufacturing by April 1, 2019 (expected by Dec 31, 2018).
- Risks: Risks include failure to close the transaction, failure to form the China JV, dilution of existing shareholders, and regulatory hurdles regarding the 522 surveillance study.
Investor Verification Checklist
- Verify the outcome of the shareholder vote required to approve the issuance of 16,000,000 shares.
- Confirm the execution of the definitive Joint Venture Agreement and the formation of the China JV by the July 1, 2018 deadline.
- Review the full financial results for Q4 and FY 2017 in the referenced press release (Exhibit 99.2) to assess the "substantial doubt" regarding going concern status.
- Monitor the execution of the License and Supply Agreements between ReWalk and the China JV.
- Assess the impact of Timwell's potential 34.8% ownership on future corporate governance and strategic direction.